Dofetilide exposure during pregnancy is associated with high blood pressure in the adult offspring

Abstract

The efficacy and safety of once-daily tiotropium+olodaterol (T+O) (2.5/5 µg or 5/5 µg) for treating chronic obstructive pulmonary disease (COPD) have been demonstrated in the large, multinational, randomized, Phase III studies TONADO® 1 and 2, which included 413 Japanese patients (~80 in each group). This study was conducted to supplement the TONADO® study data to assess long-term safety in ≥100 Japanese patients treated for 1 year in compliance with International Conference on Harmonisation guidelines. Efficacy was evaluated descriptively as a secondary end point.Patients were randomized to 52 weeks of double-blind treatment with once-daily T+O (2.5/5 or 5/5 µg) or O (5 µg) monotherapy via the Respimat® inhaler. We report the safety and efficacy data descriptively.The incidence of adverse events (AEs) was comparable in the T+O 2.5/5 µg (75.0%), T+O 5/5 µg (85.4%), and O 5 µg (80.5%) groups, with drug-related AEs being reported in 5.0%, 7.3%, and 4.9% of patients, respectively. Serious AEs were reported in 14 patients (11.5%). The change from baseline in forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h and trough FEV1 were numerically higher in the T+O treatment groups than in the O monotherapy group throughout the study period. Overall safety of T+O was comparable to that in the TONADO® studies.No safety concerns for long-term T+O treatment were identified in Japanese patients with COPD. A numerical improvement in lung function was observed with T+O treatment compared to O monotherapy.